Thomson, Craig S. http://orcid.org/0000-0002-4348-934X
Pundavela, Jay http://orcid.org/0000-0003-2861-4736
Perrino, Melissa R.
Coover, Robert A.
Choi, Kwangmin
Chaney, Katherine E.
Rizvi, Tilat A.
Largaespada, David A.
Ratner, Nancy http://orcid.org/0000-0001-5030-9354
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (5R01NS086219-05, 5R01NS086219)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Article History
Received: 2 July 2020
Revised: 21 December 2020
Accepted: 29 March 2021
First Online: 2 June 2021
Compliance with ethical standards
:
: Revolution Medicine and Boehringer Ingelheim fund some of NR’s research, unrelated to this manuscript. DAL is the co-founder and co-owner of biotechnology companies including NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immunsoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by the BioTechne Corporation), and Luminary Therapeutics, Inc. He consults for Genentech, Inc., which funds some of his research and holds equity in and serves as the Chief Scientific Officer of Surrogen, a subsidiary of Recombinetics, a genome-editing company. The business of these companies is unrelated to this manuscript.